Copied
 
 
Formål
Formål
Selskabets formål er markedsføring, salg og distribution af integrerede systemer til analyse af genetisk variation, biologisk funktion og af molekylær diagnostik, samt hermed beslægtet virksomhed.
Sidst opdateret den 09.02.2015 og angivet som gældende fra 07.12.2011 (4527 dage).
Ingen historik.
Status
Virksomhedsstatus
NORMAL.
Sidst opdateret den 09.02.2015 og angivet som gældende fra 07.12.2011 (4527 dage).
Ingen historik.
Branche
Branche
Engroshandel med medicinalvarer og sygeplejeartikler (464610).
Sidst opdateret den 07.06.2017 og angivet som gældende fra 01.01.2017 (2675 dage).
HistorikStartStop
Engroshandel med medicinalvarer og sygeplejeartikler (464610)01.01.2017
Anden fremstillingsvirksomhed i.a.n (329900)01.01.201231.12.2016
Uoplyst (999999)07.12.201131.12.2011
Revision
Revisionfravalgt
false.
Sidst opdateret den 11.03.2015 og angivet som gældende fra 07.12.2011 (4527 dage).
Ingen historik.
Revisor
Revisor
EY Godkendt Revisionspartnerselskab
Sidst opdateret den 09.02.2015 og angivet som gældende fra 10.10.2014 (3489 dage).
Form
Virksomhedsform
80.
Sidst opdateret den 21.12.2011 og angivet som gældende fra 07.12.2011 (4527 dage).
Ingen historik.
Kontakt
Ingen nuværende registrering.
Ingen historik.
Telefon
Ingen nuværende registrering.
Ingen historik.
Navne
Ingen historik.
Tegningsregel
Tegningsregel
Selskabet tegnes af en direktør alene.
Sidst opdateret den 12.06.2015 og angivet som gældende fra 12.06.2015 (3244 dage).
Fortolkning (1 tegningsmulighed)
1 direktør
HistorikStartStop
Selskabet tegnes af en direktør alene12.06.2015
Selskabet tegnes af den samlede direktion i forening07.12.201111.06.2015
Ansatte
29.04.2024
Kapital
29.04.2024
Fra årsrapport
Type af revisorbistand:Revisionspåtegning
Navn på revisionsvirksomhed:EY Godkendt Revisionspartnerselskab
Revisionsvirksomhedens CVR-nr.:30700228
Beskrivelse af revisor:State Authorised Public Accountant
Virksomhedens regnskabsklasse:Regnskabsklasse C, mellemstor virksomhed
Grundlag for konklusion (revision):Basis for opinionWe conducted our audit in accordance with International Standards on Auditing (ISAs) and additionalrequirements applicable in Denmark. Our responsibilities under those standards and requirements are furtherdescribed in the "Auditor's responsibilities for the audit of the financial statements" section of our report. Webelieve that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion. IndependenceWe are independent of the Company in accordance with the International Ethics Standards Board forAccountants' International Code of Ethics for Professional Accountants (IESBA Code) and the additional ethicalrequirements applicable in Denmark, and we have fulfilled our other ethical responsibilities in accordance withthese requirements and the IESBA Code.
Konklusion (revision):OpinionWe have audited the financial statements of Illumina Denmark ApS for the financial year 1 January -31 December 2022, which comprise income statement, balance sheet, statement of changes in equity, cash flowstatement and notes, including accounting policies. The financial statements are prepared in accordance with theDanish Financial Statements Act. In our opinion, the financial statements give a true and fair view of the financial position of the Company at31 December 2022 and of the results of the Company's operations for the financial year 1 January - 31 December2022 in accordance with the Danish Financial Statements Act.
Udtalelse om ledelsesberetningen (revision):Statement on the Management's reviewManagement is responsible for the Management's review. Our opinion on the financial statements døs not cover the Management's review, and we do not express anyform of assurance conclusion thereon. In connection with our audit of the financial statements, our responsibility is to read the Management's review and,in doing so, consider whether the Management's review is materially inconsistent with the financial statements orour knowledge obtained during the audit, or otherwise appears to be materially misstated. Moreover, it is our responsibility to consider whether the Management's review provides the information requiredunder the Danish Financial Statements Act. Based on the work we have performed, we conclude that the Management's review is in accordance with thefinancial statements and has been prepared in accordance with the requirements of the Danish FinancialStatement Act. We did not identify any material misstatement of the Management's review.
Bibranche
Ingen nuværende registrering.
Ingen historik.
Børsnoteret
29.04.2024
Ingen nuværende registrering.
Ingen historik.
Hjemmeside
29.04.2024
Ingen nuværende registrering.
Ingen historik.